New hope for liver transplant patients: CertiroBell tested against standard drug
NCT ID NCT04471441
First seen Apr 17, 2026 · Last updated Jun 08, 2026 · Updated 10 times
Summary
This study tested a drug called CertiroBell® against a standard medicine (mycophenolate mofetil) in 150 adults who received a liver transplant from a living donor. The goal was to see if CertiroBell could better prevent serious problems like organ rejection, graft loss, or death. Participants took the drug for a period after transplant, and doctors monitored their outcomes. The results help doctors understand if CertiroBell is a safe and effective option for managing transplant patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.